Oncolytic Immunotherapies for Difficult-to-Treat Cancers

November 13 2017

1

Disclaimer

Certain statements made in this presentation are forward looking statements within the meaning of the safe harbourprovisions of the United States Private Securities Litigation Reform Act of 1995. These forward looking statements are nothistorical facts but rather are based on Viralytics’ current expectations, estimates, assumptions and projections about theindustry in which Viralytics operates. Material referred to in this document that use the words ‘estimate’, ‘project’, ‘intend’,‘expect’, ‘plan’, ‘believe’, ‘guidance’ and similar expressions are intended to identify forward looking statements and shouldbe considered an at-risk statement. These forward looking statements are not a guarantee of future performance andinvolve known and unknown risks and uncertainties, some of which are beyond the control of Viralytics or which aredifficult to predict, which could cause the actual results, performance or achievements of Viralytics to be materially differentfrom those which may be expressed or implied by these statements. These statements are based on our management’scurrent expectations and are subject to a number of uncertainties and risks that could change the results described in theforward-looking statements. Risks and uncertainties include, but are not limited to, general industry conditions andcompetition, general economic factors, the impact of pharmaceutical industry regulation and health care legislation in theUnited States and internationally, and challenges inherent in new product development. Investors should be aware thatthere are no assurances that results will not differ from those projected and Viralytics cautions shareholders andprospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view ofViralytics only as of the date of this presentation. Viralytics is not under a duty to update any forward-looking statement asa result of new information, future events or otherwise, except as required by law or by any appropriate regulatoryauthority.’

2

Growing Momentum

• Lead investigational product CAVATAK® backed by growing body of clinical evidence

• Demonstrated potential across a range of indications and treatment settings

• Major opportunity for use in combination with new ‘blockbuster’ cancer immunotherapies

• Resources to conduct key global clinical trials

• Collaborative clinical trial program with Merck in lung and bladder cancer

• New studies in head and neck cancer, colorectal cancer, intravenous melanoma and uveal melanoma in advanced planning

• Corporate strategy to license, partner, or sell at key value point

CALM and CALM extension:Success in Phase 2 melanoma

trial (US)

CANON:Superficial bladder cancer (UK)

MITCI: CAVATAK / YERVOY®

Melanoma (US)

3

CAPRA: CAVATAK / KEYTRUDA®

Melanoma (US)

KEYNOTE-200: CAVATAK / KEYTRUDA®

Collaboration with Merck in lung and bladder cancer (US, AU & UK)

Strong Financial Foundation

Key Statistics

Ticker Code ASX: VLAOTCQX: VRACY

Share Price (November 10, 2017) A$0.81

Market Capitalisation A$195M

Trading Range (12-month) A$0.74 – 1.35

Institutional investors 57%

Cash position (September 30,2017) with $6.4M from Federal Government in Q4 2107

A$27.7M

Net operating cash burn 2016/17 A$11.4M

Retail

US Funds

UK FundsAustralian Funds

Other Funds

4

Leading specialist healthcare institutional investors:

- BVF Partners San Francisco

- Cormorant Asset Management Boston

- The Capital Group Los Angeles

- Quest Asset Partners Sydney

- Orbimed Advisors New York

- Abingworth London

- JCP Investment Partners Melbourne

“There’s a growing sense in the oncology community that

immune manipulation may turn out to be an even more important intervention than

chemotherapy was — maybe the most important ever”

Roger Perlmutter, President Research – Merck2

Cancer Immunotherapy:Emerging, High-Value Therapeutic Approach

• Rapidly advancing field, transforming cancer therapy

• Value of oncolytic viruses highlighted by Amgen acquisition of Biovex (TVec™) – US $425 million cash upfront; US $575 million future milestone payments

• Multiple recent transactions and collaborations

• Big pharma race to find complementary agents; Merck, BMS, Roche, Astra Zeneca, Pfizer all active

• Immuno-oncology market size forecast at US $42 billion per annum1

Opportunities for CAVATAK® in multiple settings including combinations with new cancer immunotherapies

1. Credit Suisse November 20152. Financial Times 29 May 2015

5

CAVATAK ®

Lead Product - Many Indications Under Study

• Proprietary formulation of the cold virus Coxsackievirus A 21; targets ICAM-1 receptor overexpressed on cancer cells

• Kills local and metastatic cells by both oncolytic andimmunotherapeutic activity

• Potential application across a range of cancer types:

– Intratumoral – melanoma, colorectal, head and neck

– Intravenous – melanoma, lung, metastatic bladder

– Intravesical – non-muscle invasive bladder cancer

• Potential to enhance activity of new blockbuster cancer immunotherapies

• Well tolerated in patients

• Manufactured under cGMP at Millipore Sigma (Carlsbad USA)

6

Cancer Type Rank *

Estimated New Cases in

the US in 2016 *

Breast 1st 249,260

Lung 2nd 224,390

Prostate 3rd 180,890

Colorectal 4th 134,490

Bladder 5th 76,960

Melanoma 6th 76,380

* USA National Cancer Institute, 2016

Cytoplasmic replication of CAVATAKin non-muscle invasive bladder cancer

CAVATAK®

Local and Systemic Activity

1. Oncolytic lysis and death of cancer cell

3. Stimulation of host-immune response against cancer cells

CAVATAK®

released from tumor (repeats)

infects

CAVATAK ®

binds externally to tumor cells

replicates and destroys

activates host anti-tumor

immune response

2. Viral induced tumor inflammation

7

Administration Intravenous Intratumoral Intravesical

CLINICAL TRIAL PROGRESS

CALM Phase 2 Melanoma Study

8

Day 169 (w24) irPFS

CAVATAK ® – Phase 2 CALM Melanoma Study (CAVATAK IN LATE STAGE MELANOMA)

• Leading US cancer

centres

• Responses in both

injected and metastatic

non injected tumors

• Generally well

tolerated, with no

Grade > 2 treatment-

related AEs

• Final results presented

at ASCO 2015

57 Stage IIIC and IV melanoma patientsAt least 1 injectable lesion

NOYES

10 series of multi-intratumoral CAVATAK® injections(up to 3x108 TCID50)

Day 1,3,5,8,22,43,64,85,106,127

6 Weeks later, confirmdisease progression

NO

YES

Observation only

Eligible for Extension study

9 series of multi-intratumoral

CAVATAK injections (up to 3x108 TCID50)

q21 days

9

10

IIICIV M1aIV M1bIV M1c

CR=Complete response, PR= Partial response, SD= Stable disease and PD= Progressive disease

CALM Phase 2 Trial: Impressive Response Results in Monotherapy Setting

Courtesy Dr R Andtbacka, Lead Study Investigator, Huntsman Cancer Institute as presented at ASCO 2015

Number of patients 57

Stage of Disease IIIC-IV

ir Progression-Free Survival - 6 months 38.6% (22/57)

Overall Response Rate 28.1% (16/57)

Durable Response Rate (>6mths) 21.1%

Time to Response onset 3.4 mths

One-year survival rate 75.4% (43/57)

Median Overall Survival 26 months

Best percentage change in target lesions

CAVATAK ® — Well Tolerated in Clinical Testing

+, Final analysis, treatment-related adverse events were reported from 45 of the 57 treated patients (79%) enrolled in the VLA-007 CALM CAVATAK monotherapy study;*, Only Grade 1 AE’s occurring in > 10% of patients are listed.

No drug-related grade 3 or 4 or serious

adverse events

Toxicity is a well recognized shortcoming

of existing cancertherapies

Safety: CAVATAK-Related Adverse Events+

AE Term *Grade 1 n(%)

Grade 2 n(%)

Grade 3 n(%)

Grade 4 n(%)

Injection site pain 16 (28%) 2 (4%)

Tiredness (fatigue) 15 (26%) 2 (4%)

Chills 15 (26%)

Pyrexia 7 (12%)

Injection site erythema 7 (12%)

Pain 6 (11%) 1 (2%)

Myalgia 6 (11%)

Headache 6 (11%)

11

CALM Phase 2 Trial: Extension Cohort (Biopsy Study) – When Checkpoint Inhibitors Fail

Day 0 (pre-treatment) Day 8 (post-treatment)

Courtesy Dr R Andtbacka, Lead Study Investigator, Huntsman Cancer Institute as presented at ASCO 2015

Patient 04-015 Stage IIIC melanoma on legsPrior treatment with ipilimumab and pembrolizumab

Patient 04-014 Stage IV M1c with melanoma to the leg and lungs. Prior treatment with ipilimumab and

pembrolizumab

12

Partial Response in both patients

CALM Phase 2 Trial: Activation of RIG-I Pathway and Upregulation of Immune Checkpoint Target Molecules

Day 0 (pre-treatment) Day 8 (post-treatment)

Patient 04-014 Stage IV M1c with melanoma to the leg and lungs. Prior treatment with ipilimumab and

pembrolizumab

13

CALM Phase 2 Trial: Results and Future Directions

• Successful study with primary safety endpoint achieved; secondary efficacy endpoint outcomes exceeding expectations

– Overall response rate of 28%

– Durable response in 21% patients

• CAVATAK-induced activity in non-injected distant lesions, including lung and liver metastases

Extension Trial

• Overall response rate of 31%

• CAVATAK-induced changes in the tumor:

– Increases in immune cell infiltrates

– Up-regulation of PD-L1 and other checkpoint molecules

• Observations suggest combination with checkpoint inhibitors may further enhance anti-tumor activity

14

CLINICAL TRIAL PROGRESS

Combination Therapy Studies

15

CAVATAK ® Combined with Checkpoint Inhibitors

“The world doesn’t need any more [checkpoints]. We need other things. We should be finding a way to develop other medicines beyond these”

Roger Perlmutter, President Research – Merck1

16

• Checkpoint inhibitor / CAVATAK combination preclinical results:

– Well tolerated

– Significant anti-tumor activity demonstrated

• CAVATAK combination clinical trials with approved checkpoint inhibitors underway with promising results

• Checkpoint inhibitors active in cancers that are also CAVATAK targets, including melanoma, lung and bladder

• Potential for CAVATAK in combination with future checkpoint inhibitors targeting LAG-3, TIM-3 and other immunotherapies such as IDO (in development by big pharma)

1. Financial Times 3 July 2017

%Su

rviv

al

Time- Control- Conventional Therapy- Checkpoint Inhibitor Therapy (eg anti-CTLA4)- Future Combinations with Checkpoint Inhibitors

Checkpoint Inhibitors: Room to Improve Through Combination with New Therapies

Big Pharma focused on improving activity of the checkpoint inhibitors through combination therapy

Goal: To enhance survival with manageable toxicity through combination with CAVATAK

17

CLINICAL TRIAL PROGRESS

MITCI Phase 1b Study

18

CAVATAK ® - MITCI Phase 1b StudyMELANOMA INTRA-TUMORAL CAVATAK AND IPILIMUMAB

• Company-sponsored open-label study at 9 US sites evaluating intralesional CAVATAK

and YERVOY®(ipilimumab)

• Primary Objectives are safety and response rate

• Secondary Objectives include PFS, Durable Response Rate and OS

• 60 patients with late-stage melanoma (stage IIIB-C/IV), with a current focus on patients

who have failed a single course of prior pembrolizumab or nivolumab

• Now enrolled 38 patients across all settings

• Lead investigator: Dr Brendan Curti MD, Providence Cancer Center, Portland

• Treatment with CAVATAK on days 1, 3, 5 and 8; both agents co-administered on days

22, 43, 64 and 85, with up to 19 CAVATAK treatments in total

19

CAVATAK ® - MITCI Phase 1bBest Percentage Change in Target Lesions

20

20Best Overall Response+ (irRC) Per irRCn (%)

Overall response rate 8/14(57%)

Complete response (CR) 3/14 (21%)

Partial response (PR) 5/14 (36%)

Stable disease (SD) 1/14 (7%)

Disease control rate (CR+PR+SD) 9/14 (64%)

Checkpoint therapy naïve (n=14)

* irRC criteria: Preliminary data, investigator assessed+ First response assessment at Day 106± YERVOY® FDA approved label

• Overall Response Rate of 57%

• Preliminary but encouraging response rates, versus YERVOY®

alone (11%±)

CAVATAK ® - MITCI Phase 1bBest Percentage Change in Target Lesions

21

21

Best Overall Response+ (irRC) Per irRCn (%)

Overall response rate 2/7 (29%)

Stable disease (SD) 3/7 (43%)

Disease control rate (CR+PR+SD) 5/7 (72%)

Prior single line anti-PD-1 therapy (n=7)

*, irRC criteria: Preliminary data, investigator assessed+, First response assessment at Day 106

Promising initial data in a heavily pretreated patient population

CAVATAK ® - MITCI Phase 1bChange in target lesions sum by disease

22

*, irRC criteria: Preliminary data, investigator assessed+, First response assessment at Day 106

Checkpoint therapy naïve (n=14) Single line anti-PD-1 therapy (n=7)

Promising durability in responding patients

CAVATAK ® - MITCI Phase 1bNon-injected Individual Visceral Target Lesion Responses

23

Prior anti-PD-1 therapy Checkpoint therapy naïve

• Strong anticancer activity in non-injected liver, visceral and lung lesions

CAVATAK ® - MITCI Phase 1b StudyComplete Tumor Response Stage IIIC (Pt 13-05001*)

24

CAVATAK ® - MITCI Phase 1b StudyPartial Tumor Response Stage IV M1c (Pt 13-04005*)

25

CAVATAK ® - MITCI Phase 1b Study:Preliminary Results and Outlook

• CAVATAK / YERVOY® combination is well tolerated and has displayed durable antitumour activity in injected and non injected distant systemic disease

• Safety:– No dose-limiting toxicities reported– Six Grade 3+ adverse events in 4 patients (all YERVOY-related: fatigue, elevated liver enzymes

[2], pruritis, dehydration, hyperglycemia) with an overall study Gr 3+ treatment-related AE rate of 11% (4/38 pts)

• Efficacy:– 57% (8/14) Best overall response rate in patients naïve to checkpoint therapy– 29% (2/7) Best overall response rate in patients administered prior single line anti-PD1 therapy – Preliminary but encouraging response rates, versus YERVOY alone (11%*) or other YERVOY

combination studies • Focus on an unmet need in patients who have failed prior anti-PD1 therapy • Plan to enrol 60 patients • Pivotal study in patients with high unmet need that have failed a single anti-PD1 checkpoint therapy (in

planning stage)

26

* YERVOY® FDA approved labelPotential to lead to a pivotal study

CLINICAL TRIAL PROGRESS

CAPRA Phase 1b Study

27

CAVATAK ® - CAPRA Phase 1b StudyCAVATAK AND PEMBROLIZUMAB in ADVANCED MELANOMA

• Phase 1b company-sponsored open-label study evaluating intralesional CAVATAK and KEYTRUDA® (pembrolizumab)

• Primary objective:– Safety and tolerability

• Secondary objective:– Activity as assessed by PFS at 12 months, ORR, OS, DRR and TTR

• 50 patients with late-stage melanoma (stage IIIB-C/ IV)• Now enrolled 26 patients • Lead investigator: Dr Ann Silk MD, Rutgers Cancer Institute of New

Jersey, New Brunswick• CAVATAK on Days 1, 3, 5 and 8; KEYTRUDA starting on Day 8, both

given at three-weekly intervals for up to 2 years (maximum of 19 CAVATAK injections)

28

CAVATAK ® - CAPRA Phase 1bBest Overall Response

29

Best Overall Response+ (irRC) Per irRCn (%)

Overall response rate 14/23(61%)

Disease control rate (CR+PR+SD) 18/23 (78%)

Impressive Activity in Patients with Advanced Cancer

CAVATAK ® - CAPRA Phase 1bChanges in Tumour Burden by Disease Stage

30

Promising durability in responding patients

CAVATAK ® - CAPRA Phase 1b StudyIndividual Patients Response (investigator assessed)

31

Pt1105003Stage IVM1c Partial response

Baseline

Non

-inje

cted

lung

le

sion

upp

er le

ft lo

be

Day 197

Day 113

Pt1106023Stage IIICPartial response

Baseline

Non

-Inje

cted

lym

ph n

ode

lesi

on

Righ

t int

erna

l Obt

urat

or re

gion

CAVATAK ® - CAPRA Phase 1bPreliminary Results and Outlook

32

• Best Overall Response Rate of 61% (14/23 pts) and DCR of 78% (18/23 pts)

• Tumour responses are ongoing at 12 months in 6 patients

• 4 patients have demonstrated complete responses in the target lesions

• BORR of 64% (7/11 pts) in patients with late stage IV M1c disease

• Reductions in a number of injected and non-injected visceral/non-visceral lesions

• Only two Grade 3 pembrolizumab-related adverse events in 26 enrolled patients

• Preliminary but encouraging response rates compared to KEYTRUDA alone

(33%*) or other KEYTRUDA combination studies

*Robert et al., N Engl J Med 2015; 372:2521-2532

CLINICAL TRIAL PROGRESSKEYNOTE-200 Phase 1 StudyCollaboration with Merck (MSD)

Part A – CAVATAK Monotherapy

Part B – CAVATAK and KEYTRUDA combination

33

Multi-Dose Intravenous CAVATAK ®

KEYNOTE-200 Phase 1 Study:

34

Cohort 1Any cancer

1 x108 TCID50n=3

18 subjects with advanced melanoma, prostate, NSCLC or bladder cancer with <1:16 anti-CAVATAK serum antibodies

Cohort 31 x 109 TCID50

Mandatory lesion biopsy (Day 8)

Melanoma , NSCLC, BladderAnd Prostate cancer n=3

each

IV infusions of CAVATAK in 100 mL saline over 30 min on Day

1,3,5,22,43,64,85,106,127,158

Cohort 2Any cancer

3 x 108 TCID50n=3

Part A - Completed (CAVATAK Monotherapy)

Cohort 1NSCLC or Bladder cancerCAVATAK (1 x108 TCID50)

+ Keytruda n=3

Cohort 2NSCLC or Bladder cancer

CAVATAK (3 x108 TCID50)+ Keytruda

n=3

Part B – Ongoing (CAVATAK Combination with KEYTRUDA)

Cohort 3:NSCLC or Bladder cancerCAVATAK (1 x109TCID50)

+ Keytrudan=3

IV infusions of CAVATAK in 100 mL saline over 30 min on Day 1,3,5,8,29,50,71,92,113,134,155 + IV pembrolizumab (200mg) every 3 weeks starting Day 8

No Dose Limiting Toxicities

Cohort ExpansionNSCLC (~n=40)CAVATAK(1 x109

TCID50)+ pembrolizumab

Cohort ExpansionBladder (~n=40)CAVATAK(1 x109

TCID50)+ pembrolizumab

No Dose Limiting Toxicities

35Part A - CAVATAK Monotherapy Results Best Change in Target Lesions

*irRECIST criteria: Preliminary data, investigator assessed+First response assessment at Day 42

Ten patients with stable disease

and one patients with a

confirmed partial response

36Part A - CAVATAK Monotherapy Results CAVATAK Tumor Targeting: Biopsy Viral RNA levels (day 8): Cohort 3

CAVATAK RNA present in

melanoma, lung and bladder

cancer tumor tissue following 3

intravenous doses

Well tolerated with no dose

limiting toxicity and no grade 3

or higher treatment related

adverse events

KEYNOTE-200 Phase 1b StudyCAVATAK/ Merck’s KEYTRUDA® Combination

• Phase 1b study in progress; collaboration with Merck (MSD)

• Combination of intravenous CAVATAK / KEYTRUDA in late-stage cancer patients (~ 90 patients)

– Non-small cell lung cancer

– Metastatic bladder cancer

• 17 sites in the US, Australia and UK

• Primary objective: Safety and tolerability

• Secondary objective: Efficacy

• Dose escalation complete with no dose limiting toxicity for the combination of CAVATAK and KEYTRUDA in heavily pre-treated patient population

• Currently 64 subjects enrolled at the top CAVATAK dose level used in the expansion phase

37

Potential to lead to a pivotal study

KEYNOTE-200 Phase 1b Study Preliminary First Investigator Assessment in Checkpoint Naïve Patients

38

Best percentage change in target lesions of checkpoint naïve patients + *

Encouraging early data in lung and bladder cancer

patients

Well tolerated with 11% (7 of 64 ) patients have

displayed treatment related >grade 3 adverse events

KEYNOTE-200 Phase 1b Study: Preliminary PD-L1 Expression Levels on Paired Tumour Biopsies

39

Upregulation of PD-L1 in lung and bladder cancer

patients with pre-existing low levels

Preclinical Study – Triple Combination Intravenous CAVATAK and Anti-PD-1 and IDO Inhibitor

40

Immune competent mouse melanoma model Significantly reduced tumour burden in mice treated with CAVATAK and anti-PD-1 and the

triplet combination

CLINICAL TRIAL PROGRESS

CANON Phase 1 Study

41

CAVATAK ® — CANON Phase 1 Study:(CAVATAK in NON-MUSCLE INVASIVE BLADDER CANCER)

* USA National Cancer Institute, 2016

• NMIBC is a common cancer with high unmet need and no recent

treatment advances

• Standard of care includes toxic chemotherapies

• Study to assess intravesicular CAVATAK in neo-adjuvant, frontline setting:

– Evaluated tolerability, pharmacodynamics

– Evaluated biopsies, blood and urine samples for viral replication

– Documented evidence of anti-tumor activity

• Study complete, 16 patients at Royal Surrey Hospital (UK)

• Intravesicular instillation of CAVATAK in 30 mL saline on Day 1 and/or

Day 2 +/- mitomycin C

• Transurethral resection of tumor tissue at Day 8-11

42

Cancer Type

Rank *

Estimated New Cases

in the US in 2016 *

Breast 1st 249,260

Lung 2nd 224,390

Prostate 3rd 180,890

Colorectal 4th 134,490

Bladder 5th 76,960

Melanoma 6th 76,380

43Phase 1 CANON STUDYTumor Response

Surface hemorrhage and elimination of the tumor

Complete clinical response (confirmed by histopathology)

Phase 1 CANON STUDYViral Replication

44

• CAVATAK replication up-regulates target molecules for immune-checkpoint therapies in NMIBC tissue

Phase 1 CANON STUDYUpregulation of Key Checkpoint Molecules

45

Potential to broaden partnering discussions

• Intravesicular administration of CAVATAK well tolerated - no Grade 2, 3 or 4 CAVATAK-related

Adverse Events

• Evidence of tumor targeting with viral replication

• Complete tumor response in one of the first three patients at the highest dose

• CAVATAK induces increases in immune cell infiltrates and expression of PD-L1 compared to

untreated NMIBC controls

• CAVATAK mediates increase in the “immunological heat” within the tumor micro-environment

suggesting potential for enhanced anti-tumor activity when used in combination with immune

checkpoint inhibitors

• Commercial opportunity in neoadjuvant setting - prior to transurethral resection of tumor or in

combination with checkpoint inhibitors

46CAVATAK ® — CANON Phase 1 Study: FINAL Results and Next Steps

CLINICAL TRIAL PROGRESS

New Studies in Planning Stage

47

• Phase 1b company-sponsored open-label study evaluating intralesionalCAVATAK and KEYTRUDA® (pembrolizumab)

• To be conducted in the USA

• Primary objective:

– Safety and tolerability

• Secondary objective:

– Activity as assessed by ORR, time to initial response, duration of response

• 24 patients with metastatic stage IV HNSCC for whom systemic treatment with palliative intent is indicated, or subjects with loco-regionally recurrent stage II-IV HNSCC for whom surgical salvage is indicated

• CAVATAK on Days 1, 3, 5 and 8; KEYTRUDA starting on Day 8, both given at three-weekly intervals for up to one year (maximum of 19 CAVATAK injections)

48CAVATAK ® — ITCAHN Phase 1b Study: CAVATAK AND PEMBROLIZUMAB in ADVANCED HEAD & NECK CANCER

• Phase 1b company-sponsored open-label study evaluating intravenousCAVATAK and YERVOY® (ipilimumab)

• To be conducted in the USA

• Primary objective:

– Safety and tolerability

• Secondary objective:

– Activity as assessed by ORR, disease control rate, PFS, DRR

• 6-10 patients with metastatic stage IV uveal melanoma with measurable liver lesions

• CAVATAK on Days 1, 3, 5 and 8, then at three-weekly intervals for a maximum of 11 infusions; both agents co-administered on Days 8, 29, 50 and 71

49CAVATAK ® — CLEVER Phase 1b Study: CAVATAK AND IPILIMUMAB in UVEAL MELANOMA METASTATIC TO LIVER

• Phase 1b company-sponsored open-label study evaluating intravenousCAVATAK and KEYTRUDA® (pembrolizumab)

• To be conducted in the USA • Primary objective:

– Safety and tolerability • Secondary objective:

– Activity as assessed by PFS, PFS hazard ratio, ORR, 1-year survival, overall survival

– PK profile of IV CAVATAK• 15 patients with metastatic stage IIIB-IV melanoma that has progressed

following treatment with an anti-PD-1 inhibitor• CAVATAK on Days 1, 3, 5 and 8, then at three-weekly intervals for a

maximum of 11 infusions; pembrolizumab on Day 8 then every three weeks for up to one year

50CAVATAK ® — PaCKMAN Phase 1b Study: CAVATAK AND PEMBROLIZUMAB in ADVANCED MELANOMA

• Study in planning stage • Phase 1b company-sponsored open-label study evaluating intralesional

CAVATAK and checkpoint inhibitor • Primary objective:

– Safety and tolerability of intralesional CAVATAK administration to liver metastases

• Secondary objective:– Assess the safety of 1, 2 or 3 intralesional CAVATAK injections

• 18-30 patients with colorectal cancer with at least two or more metastatic liver lesions

• CAVATAK delivered as one, two or three weekly intratumoral injections; checkpoint begins 1 week after the last CAVATAK dose then ongoing

51CAVATAK ® —Phase 1b Study: CAVATAK AND CHECKPOINT in COLORECTAL CANCER METASTATIC TO LIVER

SUMMARY

52

OVERVIEW - CAVATAK ® Clinical Trial Program

Intratumoral Intravenous Intravesicular

Phase 2: CALM studyAdvanced melanoma

N=57

Phase 2: CALM extension cohort

Advanced melanomaN=13

Phase 1: STORM study (Part A)Melanoma, NSCLC, Bladder and Prostate

cancer N=18

Phase 1: CANON studyNon-muscle invasive bladder cancer

N = 16

CAVATAK®

53

Lung Cancer and Bladder Cancer• STORM Part B / KEYNOTE-200: Merck collaboration – CAVATAK /

KEYTRUDA® Phase 1b study (N=90)Melanoma: • MITCI – CAVATAK / YERVOY® Phase 1b (N=60)• CAPRA – CAVATAK / KEYTRUDA® Phase 1b study (N=50)• PaCKMAN – Intravenous CAVATAK / KEYTRUDA® Phase 1b study (N=15)• CLEVER - Intravenous CAVATAK / YERVOY® in uveal melanoma (N=10)Head and neck/ Colorectal • ITCAHN - CAVATAK / KEYTRUDA® Phase 1b (N=24)• Colorectal cancer – CAVATAK/ checkpoint Phase 1b (planning stage)

Combination Studies

A Strong Record of Achievements

Reported positive interim results CAPRA study Achieved

Reported positive interim results MITCI study Achieved

Identified potential path to market in melanoma in setting of high unmet need Achieved

Sites initiated in US, Australia and UK with strong enrolment in KEYNOTE 200 study Achieved

Pre-clinical work to identify further target indications Achieved

Developed CAVATAK manufacture program Achieved

Well advanced in preparations for clinical studies in new indications Achieved

54

Recognition at Pre-eminent American Cancer Conferences55

Expected News Flow

Initiate CLEVER study in uveal melanoma with intravenous CAVATAK Q4 2017

Initiate ITCAHN study in head and neck cancer with intralesional CAVATAK Q1 2018

Initiate PaCKMAN study in melanoma with intravenous CAVATAK Q1 2018

Provide clinical updates on MITCI / CAPRA trials Q2 2018

Initiate study in colorectal cancer Q2 2018

Report clinical update on KEYNOTE-200 study Q2 2018

Potentially extend intravenous CAVATAK program into new indications Q2 2018

Initiate pivotal melanoma trial Q4 2018

56

CAVATAK ®

A Compelling Commercial Opportunity

• Active in a range of important cancer types with broad potential:

– To combine with a range of checkpoint molecules (eg KEYTRUDA, YERVOY)

– For use in a variety of treatment settings, including intralesional (melanoma, CRC, head and neck), intravenous (melanoma, lung, metastatic bladder) and intravesical (NMIBC)

– Increases immunological heat within the tumor micro-environment

• Well tolerated across all routes of administration

• KEYNOTE-200 – CAVATAK / KEYTRUDA combination in NSCLC and metastatic bladder completed dose escalation and recruiting strongly

• Preliminary results from MITCI (CAVATAK / YERVOY) and CAPRA (CAVATAK / KEYTRUDA) trials very encouraging and point to potential path to market in area of high unmet need

• CANON - Promising results in NMIBC – strong potential in combination with checkpoints

• Aggressive expansion of clinical program planned, with goal of driving partnering discussions and shareholder value

• Recent high value transactions in growing field of cancer immunotherapy

57

Thank You

Dr Malcolm McCollManaging Director

Email: malcolm.mccoll@viralytics.comWeb: www.viralytics.com

Follow us on:

58